13 Nov GE- It Was Bad
Michael Kramer and the clients of Mott Capital closed out the position In GE as of November 13.
GE – It Was Bad
GE what a disaster on so many fronts. The dividend cut wasn’t the worse part; it was that 2018 guidance that sank the stock. The dividend cut as we discussed, was widely expected, but the guidance for 2018, was even worse than what the bears and even I had feared. With full-year guidance cut to $1.00 to $1.07, making the stock at $20, just too expensive, with nearly no earnings growth, making it a position I could no longer hold on to.
Even with today’s decline, GE’s stock is likely still overvalued, trading at a one-year forward p/e ratio of nearly 17. In-line with Honeywell and United Technologies, GE does not deserve to trade anywhere near the valuation of either of the two former companies, in my opinion.
The direction of earnings is the only thing an investor needs to see, to know that valuation is too high, and has likely, even more, room to fall.
Could GE trade at only 15 times earnings, very likely. Could it trade at 10 times 2018 earnings, possibly? It depends on how well the company performs in the coming quarters, and how deep the issues are. It is not worth finding out from my standpoint either.
Even from a technical standpoint, there is no saving the stock. The stock could fall to a level under $15 before findings its next level of technical support. $19.75 was a critical level and it fell through it with far greater ease than anticipated.
The stock is broken, the chart is broken.
Then the questions started floating through my head, what if it was removed from DJIA? Crazy to think, but certainly not impossible.
Too much to bare, in a market that offers too many opportunities.
My opinion, my thoughts.
Two Week Free Trial Period
Also, remember to sign up for our SA Market Place Premium Content in “Reading The Markets”
Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments.
We will respond to questions in short order and will respond to questions with full-post or video segment, just not one or two-word answers.
Just $40 per Month
Free Articles Written By Mike:
Biotech Celgene Could Rebound By More Than 15%
We offer a lot of great commentaries all week talking about the major and relevant market events. Be sure to subscribe to get this all and of all free commentaries sent directly to your inbox or follow us on Twitter.
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2017 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.